Talis Biomedical

Talis Biomedical Liabilities

Delisted

The The Liabilities of Talis Biomedical (TLIS) as of Oct 31, 2026 is 25.56 M USD. In the previous year, The Liabilities was 42.55 M USD — a change of -39.94% (lower).

Liabilities

25.56 MUSD

YoY

-39.94%

Last updated:

In 2023, Talis Biomedical's total liabilities amounted to 25.56 M USD, a -39.94% difference from the 42.55 M USD total liabilities in the previous year.

The Talis Biomedical Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
3.68 M USD
Jan 1, 2019
4.12 M USD
Jan 1, 2020
16.03 M USD
Jan 1, 2021
31.85 M USD
Jan 1, 2022
42.55 M USD
Jan 1, 2023
25.56 M USD
The Talis Biomedical Liabilities history
YEARLiabilitiesYoY
25.56 MUSD-39.94%
42.55 MUSD+33.59%
31.85 MUSD+98.68%
16.03 MUSD+289.29%
4.12 MUSD+11.78%
3.68 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Talis Biomedical Stock analysis

What does Talis Biomedical do? Talis Biomedical Corp develops and commercializes the Talis One system, a cloud-enabled molecular diagnostic platform comprising a compact instrument, single-use test cartridges, and software linked to a central cloud database. The company targets healthcare providers seeking point-of-care molecular testing for infectious diseases, respiratory infections, women's health conditions, and sexually transmitted infections (STIs). Its products include assay kits for respiratory panels combining influenza A, influenza B, and COVID-19 tests, designed for use by untrained personnel. Revenue is generated through sales of the Talis One system and associated assay kits to healthcare facilities requiring rapid, accurate diagnostic solutions. The Talis One system is positioned for central laboratory-level accuracy at the point of care, appealing to clinics and hospitals needing efficient diagnostic tools. The Respiratory Panel, integrating influenza A, influenza B, and COVID-19 assays, addresses high-demand areas in infectious disease testing. The company's focus on women's health and STI-related assays expands its market reach within specialized healthcare segments. Sales of these products are directed toward healthcare providers who prioritize accessible, user-friendly diagnostic technology without requiring extensive training. Talis Biomedical Corp's commercial strategy centers on delivering diagnostic solutions that combine advanced molecular testing with ease of use. The Talis One system and its assay kits are marketed to healthcare facilities aiming to enhance diagnostic capabilities at the point of care. By targeting respiratory infections, women's health, and STIs, the company addresses key areas where rapid, accurate testing is critical. Revenue streams are derived from the sale of both the hardware platform and the consumable test kits, ensuring ongoing customer engagement through recurring purchases. Talis Biomedical is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Talis Biomedical's Liabilities

Talis Biomedical's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Talis Biomedical's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Talis Biomedical's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Talis Biomedical's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Talis Biomedical’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Talis Biomedical stock

The Liabilities of Talis Biomedical is 25.56 M USD in 2023.

The Liabilities of Talis Biomedical changed from 42.55 M USD to 25.56 M USD, representing a -39.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Talis Biomedical since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Talis Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Talis Biomedical

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Talis Biomedical